Stock Events

Nuvation Bio 

$1.78
13
+$0.01+0.56% Friday 21:00

Statistics

Day High
1.81
Day Low
1.75
52W High
2.13
52W Low
0.95
Volume
448,288
Avg. Volume
538,457
Mkt Cap
389.72M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MarExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Next
-0.16
-0.14
-0.11
-0.09
Expected EPS
-0.11
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NUVB. It's not an investment recommendation.

Analyst Ratings

4.5$Average Price Target
The highest estimate is $4.5.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
Show more...
CEO
Employees
85
Country
US
ISIN
US67080N1019

Listings